« Back to Farmacia Journal 2/2023

SERUM ANTI – MULLERIAN HORMONE IN AZOOSPERMIA APPROACH

JIAO SHU ¹, ZHIYONG LU ¹, JIE XIA ¹, MI XIANG ²*

Download Full Article PDF

This study aimed to investigate the role of serum anti - mullerian hormone (AMH) determination combined with ultrasonography and semen parameters in the diagnosis of azoospermic patients. Fifty patients with azoospermia were selected for the azoospermia group and underwent an ultrasound examination, and another 50 patients with normal semen in the same period were selected as the control group. AMH was detected in seminal plasma and serum, and semen parameters, including inhibin B (Inh - B), testosterone (T), and follicle - stimulating hormone (FSH), were measured. Seminal plasma AMH levels were higher than serum AMH levels in the normal and azoospermia groups (p < 0.05). AMH levels in seminal plasma and serum were higher in the normal group than in the azoospermia group (p < 0.05). Serum AMH levels were positively correlated with total sperm count, sperm motility rate, sperm concentration, percentage of progressively motile sperm, Inh - B, and total T and negatively correlated with follicle - stimulating hormone. The thicknesses of the epididymis head, epididymis body, and cauda epididymis in the azoospermia group were higher than those in the control group (p < 0.05). AMH level can be used as one of the biomarkers reflecting the function of Sertoli cells, which are involved in the production and growth of sperm. Ultrasound can accurately locate the prostate, ejaculatory duct, seminal vesicle, and other lesions and can provide a reliable imaging basis for the localization diagnosis of lesions in azoospermic patients.